Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...

Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Bayer CEO Bill Anderson affirmed plans to manage Xarelto's generic competition decline, as shares hit record low following Q3 ...

In its lawsuit, the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for ...

The pharmaceutical company lowered its profit target for 2024 after it posted third-quarter results that fell short of ...

Get detailed information on Rivaroxaban, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive ...

Late last week, J&J said that the new approach for Xarelto and Stelara – both drugs ... being fought between the HHS, drug manufacturers, and 340B hospitals, the latter claiming that without ...

Half of renally-cleared rivaroxaban is cleared as unchanged drug and half as inactive metabolites. ‡Potent inhibitors of both CYP3A4 and P-gp include azole antifungals (e.g., ketoconazole ...